Search
forLearn
5 / 801 resultslearn TeraCeutic™
learn Anasensyl
learn Calcium D oantothenate
learn enoxolone
Research
5 / 1000+ results
research New hair care ingredients
Several companies launched new hair care ingredients in 2011 to improve conditioning, color retention, combability, and heat protection.
research 41551 Feasibility of using an integrated RCM-OCT device to identify thin Basal Cell Carcinomas amenable to ablative therapy with a Er:YAG laser: A Prospective Observational Study
research Feature identification of skin diseases and laser therapy with a portable optical coherence imaging system
A portable imaging system shows promise for diagnosing skin diseases and checking laser treatment effects.
research 115 AE法による実機水車発電機軸受の診断(セッション4 評価・診断II)
KSR1 is crucial for certain skin tumor formation and could be a cancer therapy target.
research To Better “Serve” Your Patient’s Comfort
Improve patient comfort during medical care.
Community Join
5 / 1000+ resultscommunity Any updates or news on Gt20029?
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
community GT20029 Anageninc Market Availability
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
community SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
community SCUBE 3 (the last hair bender)
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.